Trial Profile
A Phase 1b/2, Multicenter, Open-label Study of ACP-196 in Subjects With Recurrent Glioblastoma Multiforme (GBM)
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 27 Jul 2022
Price :
$35
*
At a glance
- Drugs Acalabrutinib (Primary)
- Indications Glioblastoma
- Focus Therapeutic Use
- Sponsors Acerta Pharma
- 03 Feb 2021 Planned End Date changed from 5 Jun 2025 to 31 Dec 2025.
- 14 Jul 2020 Planned End Date changed from 1 Dec 2019 to 5 Jun 2025.
- 28 Jun 2019 Planned End Date changed from 1 Jun 2018 to 1 Dec 2019.